Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REMS Standardization Could Help Opioid Education Efforts

Executive Summary

FDA hopes to begin accepting Risk Evaluation and Mitigation Strategy documents in structured product labeling format later this year.

You may also be interested in...



Asleep At The Switch? FDA’s TIRF REMS May Not Be A Model After All

The recent US advisory committee review of the Transmucosal Immediate-Release Fentanyl REMS program is important as another marker of the fraught climate around prescription opioid abuse. But it may have broader implications for the future of drug safety regulation and the REMS model.

Restrictive REMS Is Least Favored Path For Opioid Prescriber Education

FDA advisory committee's preferred approaches – linking mandatory training to DEA registration or state medical board licensing – are outside agency's existing regulatory authority.

FDA REMS Platform Will Make Safety Plans Easy – Maybe Too Easy?

There is concern that common software package could mean more drugs end up with risk management programs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel